Analyst Julian Harrison of BTIG maintained a Buy rating on Rezolute, retaining the price target of $17.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Julian Harrison’s rating is based on the promising potential of Rezolute’s drug, ersodetug, to become the leading treatment for congenital hyperinsulinism (cHI), particularly for patients who are refractory or intolerant to the current standard treatment, diazoxide. The upcoming Phase 3 sunRIZE trial results, expected in December 2025, are anticipated to confirm ersodetug’s efficacy and safety, which could position it as a first-line treatment option.
Harrison highlights the significant market opportunity for ersodetug, given the large number of cHI patients in the US who require effective therapeutic intervention. The drug’s favorable safety profile and expected efficacy, demonstrated in previous trials, contribute to its potential to meet or exceed the trial’s efficacy benchmarks. This, coupled with the high unmet need in the cHI patient population, underpins Harrison’s optimistic outlook and Buy rating for Rezolute’s stock.
According to TipRanks, Harrison is a 5-star analyst with an average return of 30.8% and a 55.52% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Cullinan Management, Oruka Therapeutics, and Rezolute.
In another report released on November 14, H.C. Wainwright also maintained a Buy rating on the stock with a $14.00 price target.